Repositioning Brusatol as a Transmission Blocker of Malaria Parasites

ACS Infect Dis. 2024 Oct 11;10(10):3586-3596. doi: 10.1021/acsinfecdis.4c00434. Epub 2024 Oct 1.

Abstract

Currently, primaquine is the only malaria transmission-blocking drug recommended by the WHO. Recent efforts have highlighted the importance of discovering new agents that regulate malarial transmission, with particular interest in agents that can be administered in a single low dose, ideally with a discrete and Plasmodium-selective mechanism of action. Here, our team demonstrates an approach to identify malaria transmission-blocking agents through a combination of in vitro screening and in vivo analyses. Using a panel of natural products, our approach identified potent transmission blockers, as illustrated by the discovery of the transmission-blocking efficacy of brusatol. As a member of a large family of biologically active natural products, this discovery provides a critical next step toward developing methods to rapidly identify quassinoids and related agents with valuable pharmacological therapeutic properties.

Keywords: brusatol; drug discovery; malaria; natural products; quassinoids; transmission blocking.

MeSH terms

  • Animals
  • Antimalarials* / chemistry
  • Antimalarials* / pharmacology
  • Drug Repositioning
  • Humans
  • Malaria* / drug therapy
  • Malaria* / parasitology
  • Malaria* / transmission
  • Mice
  • Plasmodium / drug effects
  • Plasmodium falciparum / drug effects
  • Quassins* / chemistry
  • Quassins* / pharmacology

Substances

  • Antimalarials
  • Quassins
  • brusatol